Clinical Trials on Hemophilia B

Total 6610 results

Bayer

Completed

Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Hemophilia A

Bulgaria, Spain, Italy, Poland, Greece, Norway, Denmark
Takeda

Completed

A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate

Hemophilia A

Canada
Takeda

Completed

A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophilia A (HAPKIDO)

Hemophilia A

Russian Federation
Chulalongkorn University

Completed

Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients

Hemophilia

Thailand
Hospices Civils de Lyon

Completed

Evaluation of the Training Program for Community Pharmacists for Dispensing Emicizumab (HEMLIBRA®) in France (PASODOBLEDEMI1)

Hemophilia A

France
Bayer
American Thrombosis and Hemostasis Network

Terminated

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

Hemophilia A

United States
Swedish Orphan Biovitrum
Bioverativ Therapeutics Inc.

Completed

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies (ReITIrate)

Hemophilia A

Ireland, United Kingdom, Germany, United States, Canada, Slovenia, Sweden
Green Cross Corporation
Dream CIS, Inc.

Completed

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

Hemophilia

Korea, Republic of
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Hemophilia A

United States, France, Austria, United Kingdom, Germany, Belgium, Canada, Italy, Sweden
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors (STASEY)

Hemophilia A

Canada, Australia, Belgium, India, Germany, Israel, Italy, Spain, Colombia, United Kingdom, Netherlands, Saudi Arabia, Hungary, Guatemala, Russian Federation, Poland, Switzerland, Finland, Panama, Brazil, Mexico, Portugal, Romania, Sw...
Baxalta now part of Shire

Completed

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States
Baxalta now part of Shire

Completed

Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A

Hemophilia A

Germany
Baxalta now part of Shire

Terminated

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Hemophilia A

United States, South Africa, United Kingdom
Baxalta now part of Shire

Completed

Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients

Hemophilia A

Czechia, Bulgaria, Hungary, Poland
Baxalta now part of Shire
Baxter BioScience

Completed

ADVATE Post Authorization Safety Surveillance

Hemophilia A

United States
Genentech, Inc.

Terminated

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Hemophilia A

United States
Octapharma

Terminated

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (PREVAIL)

Hemophilia A

Canada
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Unknown

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
The Hospital for Sick Children

Completed

Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A

Hemophilia A

Canada
Nantes University Hospital

Completed

MOTHIF II : THERAPEUTIC MANAGEMENT AND USE OF CLOTTING FACTORS IN HEMOPHILIA A & B IN FRANCE II (MOTHIF II)

Hemophilia

France
Sinocelltech Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Parexel; Q2...

Completed

Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A

Hemophilia A

China
Bayer

Withdrawn

Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia

Hemophilia
Bayer

Completed

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (ECHO)

Hemophilia A

United States, Japan, United Kingdom, Spain
Pfizer

Completed

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Hemophilia A

United States, Argentina, Austria, Colombia, Croatia, Jordan, Mexico, New Zealand, Oman, Peru, Poland, Romania, Turkey
Pfizer

Completed

Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO

Hemophilia A

Italy
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Hemophilia A

Italy, United States, Netherlands, United Kingdom, Germany, New Zealand, Belgium, France
Bayer

Completed

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Hemophilia A

United States
Neuroscience Research Australia
Sydney Children's Hospitals Network; Royal Children's Hospital; The George Institute

Completed

Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia (MOrPH)

Hemophilia
Hampshire Hospitals NHS Foundation Trust

Completed

National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A (UK-PK)

Hemophilia A

United Kingdom
Bayer

Completed

Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A

Hemophilia A

United States
The Hospital for Sick Children

Completed

Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia

Hemophilia A

Canada
Catalyst Biosciences

Completed

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Hemophilia A

United States, Belgium, Hungary, Italy, New Zealand, South Africa, Turkey, United Kingdom
Emory University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Inhibitor Development in Patients With Hemophilia A Undergoing Surgery (PASs)

Hemophilia A

United States
CancerCare Manitoba
The Hospital for Sick Children; Novo Nordisk A/S

Completed

Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function

Hemophilia A

Canada
Bayer

Completed

A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A (Leopold II)

Hemophilia A

China, United States, Ukraine, Taiwan, Mexico, Thailand, Romania, Colombia, Turkey, Serbia, Russian Federation, South Africa, Japan, Indonesia, Argentina, Czech Republic, India, Slovakia
Sinocelltech Ltd.

Unknown

Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A

Hemophilia A

China
Chulalongkorn University

Completed

Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients

Hemophilia A

Thailand
Nanjing Medical University

Unknown

Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A

Hemophilia A
Cairo University
Affiliated Hospital to Academy of Military Medical Sciences

Unknown

Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia

Hemophilia

Egypt
Bayer

Completed

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Hemophilia A

Croatia, Germany, Saudi Arabia, Kazakhstan, Romania, Russian Federation, Slovenia, Bahrain, United Arab Emirates, Bosnia and Herzegovina, Israel, Kuwait, Libyan Arab Jamahiriya, Morocco, Oman, Qatar, Tunisia
Bayer

Completed

Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222

Hemophilia A

Bulgaria
Green Cross Corporation
Atlantic Research Group

Unknown

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

Hemophilia A

United States
rEVO Biologics

Completed

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (rhFVIIa)

Hemophilia

Netherlands, United States
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI); Genentech, Inc.

Completed

Rituximab to Treat Severe Hemophilia A (RICH)

Hemophilia A

United States
Hospices Civils de Lyon

Terminated

Individually Tailored Prophylaxis in Patients With Severe Hemophilia A (OPTIPHASE)

Hemophilia A

France
Georgetown University

Completed

Biomarkers Serum Collection Methodology Pilot Study

Hemophilia A

United States
AstraZeneca

Completed

A Feasibility Study to Collect Data in Patients With Haemophilia

Hemophilia

Sweden
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A

Hemophilia A
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto AF in Severe Hemophilia A

Hemophilia A
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Factor VII Deficiency | Hemophilia A With Inhibitor | Glanzmann Thrombasthenia

United States, India, Italy, Russian Federation, Ukraine

3

Subscribe